Skip to main content

Advertisement

Log in

Rheumatoid Arthritis Disease Progression Modeling

Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

Time progression models provide a significant advantage in developing clinical trials and can also be used to elicit comparisons among therapeutic agents. The authors performed a meta-analysis to construct a time progression model for rheumatoid arthritis (RA), an area of significant interest for pharmaceutical development, using the ACR20 end point. Compounds studied were chiefly monoclonal antibodies that were used in conjunction with methotrexate. The study shows that an exponential time response model adequately fits the data. From the modeling, a distribution of effects for biological RA therapies can be provided.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Amgen. 10-Q. Filed August 8, 2012; Thousand Oaks, California.

  2. Abbott. 10-K. Filed February 21, 2012; Abbott Park, Illinois.

  3. Johnson and Johnson. 10-K. Filed February 22, 2012; New Brunswick, New Jersey.

  4. Reeve R, Turner IR. Pharmacodynamic models: parameterizing the Hill equation, Michaelis-Menten, and the logistic curve, and relationships among these models. J Biopharm Stat. In press.

  5. Demin I, Hamrén B, Luttringer O, Pillai G, Jung T. Longitudinal model-based meta-analysis in rheumatoid arthritis: an application toward model-based drug development. Clin Pharmacol Ther. 2012;92:352–359.

    Article  CAS  Google Scholar 

  6. Siegal J, Zhen B-G. Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in favor. Arthritis Rheum. 2005;52:1637–1641.

    Article  Google Scholar 

  7. Harth M, Pope J. The measure of our measures. Rheumatology. 2004;43:1465–1467.

    Article  CAS  Google Scholar 

  8. Welsing PMJ, Landewe BM, van Riel PLCM, et al. The relation between disease activity and radiological progression in patients with rheumatoid arthritis: a longitudinal analysis. In: Welsing PMJ, ed. Interrelations Between Process and Outcome Measures Over the Course of Rheumatoid Arthritis. 2005. http://repository.ubn.ru.nl/bitstream/2066/49209/1/49209.pdf.

  9. Welsing PMJ, Landewe RBM, van Riel PLCM, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum. 2004;50:2082–2093.

    Article  Google Scholar 

  10. Gabrielson J, Weiner D. Pharmacokinetic/Pharmacodynamic Data Analysis: Concepts and Applications. Stockholm, Sweden: Swedish Pharmaceutical Press; 2000:185.

    Google Scholar 

  11. Lacroix BD, Lovern MR, Stockis A, Sargentini-Maier ML, Karlsson MO, Friberg LE. A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2009;86:387–395.

    Article  CAS  Google Scholar 

  12. Anderson JJ, Bolognese JA, Felson DT. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study. Arthritis Rheum. 2003;48:3031–3038.

    Article  Google Scholar 

  13. Hu C, Xu Z, Zhang Y, Rahman MU, Davis HM, Zhou H. Population approach for exposure-response modeling of golimumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2011;51:639–648.

    Article  CAS  Google Scholar 

  14. Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck C. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther. 2003;73:348–365.

    Article  CAS  Google Scholar 

  15. Thomas N. An example of simulation-based calculations of the probability of technical success. Presented at: the Joint Statistical Meetings; July 30 to August 2, 2012; San Diego, California.

  16. Lindstrom MJ, Bates DM. Nonlinear mixed effects models for repeated measures data. Biometrics. 1990;46:673–687.

    Article  CAS  Google Scholar 

  17. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum. 2004;50:1400–1411.

    Article  CAS  Google Scholar 

  18. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35–45.

    Article  CAS  Google Scholar 

  19. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study. Arthritis Rheum. 2008;58:2968–2980.

    Article  CAS  Google Scholar 

  20. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63:609–621.

    Article  CAS  Google Scholar 

  21. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88–96.

    Article  CAS  Google Scholar 

  22. Keystone E, van der Heijde DM, Mason D Jr., et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58:3319–3329.

    Article  CAS  Google Scholar 

  23. Smolen J, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009;68:797–804.

    Article  CAS  Google Scholar 

  24. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60:2272–2283.

    Article  CAS  Google Scholar 

  25. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis. 2009;68:789–796.

    Article  CAS  Google Scholar 

  26. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932–1939.

    Article  CAS  Google Scholar 

  27. Schiff M, Keiserman M, Codding C, et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Ann Rheum Dis. 2008;70:2003–2007.

    Article  Google Scholar 

  28. St Clair EW, van der Heijde DM, Smolen JS, et al. Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset study group combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432–3443.

    Article  CAS  Google Scholar 

  29. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept. Arthritis Rheum. 2005;50:2263–2271.

    Article  Google Scholar 

  30. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114–1123.

    Article  CAS  Google Scholar 

  31. Bathon JB, Martin R, Fleischmann R, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2005;343:1586–1593.

    Article  Google Scholar 

  32. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet. 2004;363:675–681.

    Article  CAS  Google Scholar 

  33. Billingsley P. Probability and Measure. 2nd ed. New York: John Wiley & Sons; 1986.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Russell Reeve PhD.

Additional information

Dr Pang was at Quintiles, Durham, NC, USA, when this study was performed.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reeve, R., Pang, L., Ferguson, B. et al. Rheumatoid Arthritis Disease Progression Modeling. Ther Innov Regul Sci 47, 641–650 (2013). https://doi.org/10.1177/2168479013499571

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479013499571

Keywords

Navigation